Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma

Published:2019-09-30 Issue:12 Volume:33 Page:881-890
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Lee Inki,Byun Byung Hyun,Lim Ilhan,Kim Byung Il,Choi Chang Woon,Kim Kyeong Min,Shin Dong-Yeop,Kang Hye Jin,Lim Sang Moo

Funder

Ministry of Science and ICT of the Republic of Korea

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12149-019-01401-5.pdf

Reference20 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

2. England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging. 2017;44(3):517–32.

3. Chiu BC, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25.

4. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–68.

5. Eskian M, Khorasanizadeh M, Zinzani PL, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy. 2018;10(8):699–711.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials;Cancers;2021-11-07

2. KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future;Nuclear Medicine and Molecular Imaging;2021-08-23

3. Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model;Scientific Reports;2021-06-18

4. Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab;Annals of Nuclear Medicine;2021-04-03

5. Effects of rituximab therapy on B cell differentiation and depletion;Clinical Rheumatology;2020-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3